GlassScriptPhysician profile
I-Wen Chang
NPI 1912034471
$10,169.31
in general payments reported to CMS, 2019-2025
62 companies · $2,749 in 2025
The $2,749 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.89 · 2020: $15.57 · 2021: $71.74 · 2022: $1,768 · 2023: $3,219 · 2024: $2,290 · 2025: $2,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,163 · Education: $95.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,163.28 |
| Education | $95.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,137.91 | 2022-2025 | Cabometyx |
| Janssen Biotech, INC. | $723.57 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals LP | $670.42 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Pfizer INC. | $656.47 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $485.80 | 2022-2025 | |
| Glaxosmithkline, LLC. | $468.01 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $448.11 | 2022-2025 | Enhertu, Datroway |
| Celgene Corporation | $443.63 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $433.75 | 2021-2023 | Adcetris, Tivdak, Padcev |
| Merck Sharp & Dohme LLC | $387.45 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $256.11 | 2021-2025 | Polivy, Tecentriq, Lunsumio |
| Eisai INC. | $240.91 | 2023-2025 | |
| Incyte Corporation | $207.95 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Jazz Pharmaceuticals INC. | $199.76 | 2023-2025 | Zepzelca |
| Abbvie INC. | $198.66 | 2023-2025 | Venclexta |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $167.16 | 2020-2025 | Xtandi, Vyloy, Padcev |
| Coherus Oncology, INC. | $164.99 | 2022-2025 | Loqtorzi |
| Stemline Therapeutics INC. | $157.83 | 2023-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $145.12 | 2022-2025 | |
| Amgen INC. | $134.86 | 2022-2023 | Lumakras, Kyprolis, Vectibix |
| Janssen Scientific Affairs, LLC | $132.45 | 2024 | Rybrevant |
| Genmab U.S., INC. | $125.00 | 2024 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $107.24 | 2022-2024 | Opdivo |
| Beone Medicines USA, INC. | $106.92 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $105.77 | 2023-2024 | Ultomiris |
| Beigene USA, INC. | $105.55 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $105.48 | 2022-2023 | Epkinly, Imbruvica |
| Dendreon Pharmaceuticals LLC | $100.84 | 2023-2024 | Provenge |
| Adc Therapeutics America, INC. | $98.87 | 2022-2025 | |
| Puma Biotechnology, INC. | $91.39 | 2022-2025 | |
| Genzyme Corporation | $89.84 | 2022-2025 | |
| Foundation Medicine, INC. | $89.01 | 2022-2023 | Foundationone Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.53 | 2023 | Gilotrif |
| Myriad Genetic Laboratories, INC. | $64.32 | 2022-2024 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $63.67 | 2019-2024 | Onivyde |
| Lilly USA, LLC | $62.75 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $58.05 | 2024-2025 | Iclusig, Ninlaro |
| Karyopharm Therapeutics INC. | $57.57 | 2022-2025 | Xpovio |
| Array Biopharma INC | $57.35 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Tempus Ai, INC | $56.85 | 2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $54.02 | 2023-2024 | |
| Sobi, INC | $52.52 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $50.48 | 2024 | |
| Gilead Sciences, INC. | $49.55 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $43.48 | 2025 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $42.79 | 2022 | |
| Deciphera Pharmaceuticals INC. | $40.34 | 2023-2025 | Qinlock, Romvimza |
| Kite Pharma, INC. | $39.11 | 2023-2025 | Yescarta |
| Blueprint Medicines Corporation | $37.46 | 2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $37.44 | 2022-2023 | Libtayo |
| Sun Pharmaceutical Industries INC. | $32.70 | 2025 | |
| Inari Medical, INC. | $30.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $24.14 | 2023 | Xarelto |
| Legend Biotech USA INC. | $21.93 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $21.49 | 2024 | Zoladex |
| Mirati Therapeutics, INC. | $21.26 | 2023 | Krazati |
| Ferring Pharmaceuticals INC. | $20.19 | 2024 | Adstiladrin |
| Immunogen, INC. | $19.36 | 2023 | Elahere |
| Caris Mpi, INC. | $19.10 | 2025 | Mi Cancer Seek |
| Exact Sciences Corporation | $18.45 | 2024 | Cologuard Collection Kit |
| Cti Biopharma Corp. | $16.88 | 2023 | Vonjo |
| Fortovia Therapeutics, INC. | $3.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw I-Wen Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.